The Zacks Analyst Blog Eli Lilly, Medtronic, Intuitive Surgical, Regeneron Pharmaceuticals and Johnson & Johnson
View original at finance.yahoo.comThe Zacks Analyst Blog Eli Lilly, Medtronic, Intuitive Surgical, Regeneron Pharmaceuticals and Johnson & Johnson For Immediate Releases Chicago, IL – January 6, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Zacks top stock-picking strategies have achieved average gains of +48.4%, +50.2% and +56.7% per year since 2000, compared to S&P 500's +7.7% average gain per year
80% confidenceRegeneron Pharmaceuticals has an expected revenue and earnings growth rate of 4.9% and -0.4%, respectively, for the current year
80% confidenceJohnson & Johnson has an expected revenue growth rate of 5% for the current year
80% confidenceJohnson & Johnson carries a Zacks Rank #3 (Hold)
80% confidenceEli Lilly currently sports a Zacks Rank #1 (Strong Buy)
80% confidenceRegeneron carries a Zacks Rank #2
80% confidenceISRG has an ROE of 15.1% compared with the industry's ROE of -18.7% and the S&P 500's ROE of 17%
80% confidenceJohnson & Johnson has an expected earnings growth rate of 5.7% for the current year
80% confidenceEli Lilly has an expected earnings growth rate of 41.3% for the current year
80% confidenceAI fundamentally reshaped the medical landscape in 2024, revolutionizing diagnostics, treatment and operational efficiency
80% confidenceJohnson & Johnson carries a Zacks Rank #3 (Hold)
80% confidenceREGN has an ROE of 13.8% compared with the industry's ROE of -65.41% and the S&P 500's ROE of 17%
80% confidenceThe healthcare sector is generally defensive in nature with most stocks characterized as low-beta and dividend paying, but extensive use of AI has transformed several into potential high-growth providers
80% confidenceJNJ has an ROE of 32.7% compared with the industry's ROE of 37% and the S&P 500's ROE of 17%
80% confidenceRegeneron Pharmaceuticals has an expected earnings growth rate of -0.4% for the current year
80% confidenceMDT has an ROE of 14.9% compared with the industry's ROE of -2.5% and the S&P 500's ROE of 17%
80% confidenceIntuitive Surgical carries a Zacks Rank #2 (Buy)
80% confidenceJohnson & Johnson has an expected revenue and earnings growth rate of 5% and 5.7%, respectively, for the current year
80% confidenceRegeneron put up a decent performance in 2025 as revenues grew despite declining sales of its lead drug Eylea
80% confidenceMedtronic has an expected earnings growth rate of 2.7% for the current year (ending April 2026)
80% confidenceMedtronic carries a Zacks Rank #2 (Buy)
80% confidenceThe supercomputer will power an AI factory, a specialized computing infrastructure that manages the entire AI lifecycle from data ingestion and training to fine-tuning and high-volume inference
80% confidenceEli Lilly has an expected revenue and earnings growth rate of 22.3% and 41.3%, respectively, for the current year
80% confidenceMedtronic has an expected revenue and earnings growth rate of 7.5% and 2.7%, respectively, for the current year ending April 2026
80% confidenceAI fundamentally reshaped the medical landscape in 2024, revolutionizing diagnostics, treatment and operational efficiency
80% confidenceIntuitive Surgical has an expected revenue and earnings growth rate of 14.3% and 11.1%, respectively, for the current year
80% confidenceEli Lilly has a Zacks Rank #1 (Strong Buy)
80% confidenceThe supercomputer will power an AI factory, a specialized computing infrastructure that manages the entire AI lifecycle from data ingestion and training to fine-tuning and high-volume inference.
80% confidenceHypertension presents a multi-billion-dollar opportunity as Medtronic ramps up for CMS coverage of Symplicity
80% confidenceEli Lilly has a return on equity of 109.5% compared with the industry's ROE of 37% and the S&P 500's ROE of 17%
80% confidence